GSK
Stock Details
GSK is GSK plc's stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 43.66$. Average daily volumn in 3 months 5.67M. Market cap 110.87B
Stock symbol : GSK. Exchange : NYSE. Currency : USD Lastest price : 43.44$. Total volume : 412.84k. Market state REGULAR Click reload if you want to check the lastest price on market!!!
GSK plc (GSK)
Last Price
43.44$Change
0.33Volume
412.84k
| Previous Close | 43.11 |
| Open | 43.31 |
| Day Range | 43.22-43.46 |
| Bid | 43.27 x 800 |
| Ask | 43.28 x 1.1k |
| Volume | 412.84k |
| Average Volume | 5.67M |
| Market Cap | 110.87B |
| Beta | 0.25 |
| 52 Week Range | 37.80-46.97 |
| Trailing P/E | 17.81 |
| Foward P/E | 12.41 |
| Dividend (Yield %) | 4.61% |
| Ex-Dividend Date | 2022-05-19 |
Financial Details
Organization
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory... , HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Market Cap:
110.87BRevenue:
34.11BTotal Assets:
79.1BTotal Cash:
4.27B
News about "GSK plc"
GSK plc (GSK) and the Battle of Fundamentals vs. Technicals
Source from : newsheater - 11 hours ago
GSK plc (NYSE:GSK) went down by -0.44% from its latest closing price compared to the recent 1-year high of $46.97. The company’s stock price has collected -0.55% of loss in the last five trading ...See details»
GSK plc (LON:GSK) Insider Emma Walmsley Acquires 7 Shares
Source from : Defense World - 15 hours ago
GSK plc (LON:GSK – Get Rating) insider Emma Walmsley bought 7 shares of the business’s stock in a transaction that occurred on Monday, July 4th. The shares were bought at an average cost of GBX 1,799 ...See details»
Right Now May Be the Best Buy-In Window for GSK plc (GSK)
Source from : investchronicle - 1 days ago
GSK plc (GSK) is priced at $43.11 after the most recent trading session. At the very opening of the session, the stock price was $43.17 and reached a high price of $43.325, prior to closing the ...See details»
Ipswich Investment Management Co. Inc. Has $443,000 Stock Position in GSK plc (NYSE:GSK)
Source from : Defense World - 12 hours ago
Ipswich Investment Management Co. Inc. lowered its position in shares of GSK plc (NYSE:GSK – Get Rating) by 9.8% in the first quarter, HoldingsChannel reports. The firm owned 10,165 shares of the ...See details»
GSK investor support for spin-off vindicates rejection of Unilever bid, says chief
Source from : The Financial Times - 1 days ago
GlaxoSmithKline’s chief executive said a shareholder vote in favour of spinning off its consumer healthcare business vindicated the UK drugmaker’s decision to turn down a £50bn takeover offer from ...See details»
At $43.12, GSK plc (GSK) Is Worth Your Consideration
Source from : stocksregister - 7 days ago
GSK plc (NYSE:GSK) at last check was buoying at $43.12 on Thursday, June 30, with a fall of -1.50% from its closing price on previous day. Taking a look at stock we notice that its last check on ...See details»
GSK plc (GSK): Does this stock hold the most enticing factor today?
Source from : investchronicle - 8 days ago
GSK plc (GSK) is priced at $43.35 after the most recent trading session. At the very opening of the session, the stock price was $43.59 and reached a high price of $43.75, prior to closing the session ...See details»
Investors Back GSK’s Demerger Plan
Source from : KamCity - 8 hours ago
The demerger is a key plank of GSK’s turnaround strategy to focus on its core vaccines and pharmaceuticals businesses. Haleon, which owns brands such as Sensodyne, Panadol, Advil, and Centrum, made a ...See details»
Sareum Holdings Says GSK Completes Acquisition of Sierra Oncology
Source from : MarketWatch - 3 days ago
By Michael Susin Sareum Holdings PLC said on Monday that GSK PLC has completes the acquisition of Sierra Oncology for US$1.9 billion in cash and ...See details»
GSK's conÂsumer health spinÂoff HaÂleÂon preps launch with $12B+ in debt
Source from : ENDPOINTS NEWS - 1 days ago
GSK’s consumer health spinoff Haleon will make its big debut in just over a week — but with some serious debt in tow, according to the company. When it lists on the London Stock Exchange on July 18, ...See details»
InÂvestors to tap GSK's reÂsearch site for new bilÂlion-dolÂlar life sciÂences camÂpus — reÂport
Source from : ENDPOINTS NEWS - 2 days ago
Two investors, armed with substantial financial backing, are taking advantage of 33 acres of land at a Big Pharma R&D hub to build a new life sciences campus. A report in The Times and retweeted by ...See details»
Atticus Wealth Management LLC Purchases 500 Shares of GSK plc (NYSE:GSK)
Source from : ETF Daily News - 10 days ago
Atticus Wealth Management LLC raised its position in shares of GSK plc (NYSE:GSK – Get Rating) by 69.8% in the first quarter, according to the company in its most recent filing with the SEC. The ...See details»
GSK Shares Encouraging Data From Chronic Hepatitis B Candidate
Source from : YAHOO!Finance - 10 days ago
GSK plc (NYSE: GSK) announced promising interim results from the B-Clear phase 2b trial of bepirovirsen in people with chronic hepatitis B (CHB). The data showed that bepirovirsen reduced hepatitis B ...See details»
Sanofi-GSK Reports Positive Data From COVID-19 Beta-containing Vaccine Trial
Source from : Nasdaq - 13 days ago
Drug majors Sanofi (SNYNF, SNY) and GSK plc (GSK.L) announced Friday positive data from their vaccine trial which evaluated an adjuvanted bivalent D614 and Beta (B.1.351) vaccine candidate. Sanofi-GSK ...See details»